PHIO — Phio Pharmaceuticals Corp.
Is PHIO overbought or oversold? Here is the current MarketMoodz read.
Phio Pharmaceuticals Corp. (PHIO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.75. The rating moved from Strong Oversold to Oversold on November 10, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.75
- Last changeMoved from Strong Oversold to Oversold on November 10, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Phio Pharmaceuticals Corp. (PHIO) is a small, development-stage biopharma whose valuation is driven by clinical progress, partnerships and financing activity. Financial health is likely constrained by limited commercial revenue, making cash runway and potential dilutive financings key near-term considerations. The company benefits from upside potential tied to binary pipeline catalysts but faces large downside if trial or regulatory outcomes are negative. Market context is mixed: investor flows currently favor large-cap pharma and defensive healthcare, which can reduce investor appetite for microcap biotech names. Near-term scenarios include steady trading around current levels absent new data, meaningful appreciation on positive clinical or licensing news, or downward pressure if funding needs force dilutive raises.
Key factors
- Early-stage, R&D-focused business model with limited or no commercial revenue, making near-term valuation highly dependent on clinical progress and partnerships
- Cash runway and financing posture likely to be primary drivers of share moves; sector trend toward convertible financings increases dilution risk for mid/small-cap biotechs
- Pipeline-readout binary events (trial updates, INDs, or partner licensing deals) can create significant volatility and upside if positive
- Market technicals: low liquidity and microcap trading patterns can amplify swings; sector flows currently favor large-cap pharma over small biotech
- Absence of meaningful social/research signals or EDGAR filing detail in the provided data increases uncertainty around near-term catalysts
Risks
- Clinical or regulatory setbacks for lead programs, which would materially reduce valuation
- Insufficient cash runway leading to near-term dilutive financing (equity or convertible instruments)
- Competitive pressure from larger, better-funded biotech and pharma companies with overlapping modalities or therapeutic targets
- Low daily trading volume and investor attention risk causing elevated volatility and limited ability to exit positions
- Macro risk and rotation into large-cap defensive pharma could reduce investor appetite for microcap biotech names
See today's live rating, score and targets
Members see the live hourly rating for PHIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.